Search results
Added:
1 year ago
In this programme, a leading faculty delve into the groundbreaking advancements in the treatment of severe tricuspid regurgitation with the innovative EdwardsEVOQUE Tricuspid Valve Replacement System. This session features an informative "Live in a Box" transcatheter tricuspid replacement valve case by Prof Jörg Hausleiter. It provides a comprehensive analysis of the patient selection criteria,…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a…
View more
Added:
2 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more
Start date:
Apr 18, 2024
Added:
1 year ago
Learn from your interventional, imaging and heart failure colleagues about the latest in recognizing and treating patients with mitral and tricuspid valve disease. Explore case-based discussions, brush up on the latest clinical data and guidelines and learn more about new approved technologies for your valvular disease patients.
View more
Added:
4 months ago
New York Valves 25 - Quantitative findings from Tri-QOL showed a strong correlation between tricuspid regurgitation (TR) reduction and KCCQ improvement after transcatheter tricuspid valve intervention (TTVI).Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, Kansas City, US) discusses findings from a quantitative analysis from the Tri-QOL study which aimed to assess the optimal result…
View more
Added:
1 year ago
Added:
5 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating…
View more
Start date:
Aug 06, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday…
View more
Added:
1 week ago
TCT 2025 - Dr Nadira Hamid (Allina Health Minneapolis Heart Institute, Minneapolis, US) is joined by Dr Jonathan Schwartz (Sanger Heart and Vascular Institute, Charlotte, US) to discuss the lessons learned from the update of the TRILUMINATE Pivotal Trial (NCT03904147), investigating tricuspid TEER (transcatheter edge-to-edge repair) in 800+ patients with severe tricuspid regurgitation.Findings at…
View more